Amplitude insider sells 10,000 shares after option exercise; prior 10b5-1 sales disclosed
Rhea-AI Filing Summary
Amplitude, Inc. (AMPL) filing a Form 144 notifies the sale of 10,000 common shares by a person who exercised options on 09/15/2025. The broker listed is Morgan Stanley Smith Barney LLC and the sale's aggregate market value is reported as $110,700, with an approximate sale date of 09/15/2025 on NASDAQ. The filing shows the shares were acquired by exercise of stock options from the issuer and paid in cash on the acquisition date.
The notice also reports two recent 10b5-1 plan sales by Erica F. Schultz totaling 15,000 shares across 07/15/2025 and 08/15/2025 with gross proceeds of $94,205.25 and $85,968.00 respectively. The filer affirms no undisclosed material adverse information and references potential reliance on a 10b5-1 trading plan.
Positive
- Compliance disclosure of option exercise and sale details, including broker and aggregate value
- Prior 10b5-1 sales disclosed for the same holder, indicating planned, rule-compliant insider selling
- Attestation that no undisclosed material adverse information is known by the seller
Negative
- None.
Insights
TL;DR: A small option exercise and planned sale of 10,000 AMPL shares via Rule 144; recent 10b5-1 sales for the same holder are disclosed.
The Form 144 documents an insider-originated sale following option exercise on the same date, with 10,000 shares offered through Morgan Stanley at an aggregate value of $110,700. Recent 10b5-1 execution history shows systematic planned sales of 7,500 shares in July and 7,500 in August by Erica F. Schultz, yielding modest proceeds. Relative to the company's reported outstanding shares of 102,111,652, these transactions are immaterial from a supply/dilution perspective. The representation that no material nonpublic information exists and the mention of a 10b5-1 plan are standard compliance features. Investors should view this as routine insider liquidity rather than a signal of company-wide developments.
TL;DR: Filing is procedurally correct and indicates compliance with insider-trading rules; disclosed 10b5-1 sales reduce regulatory risk.
The notice details that the securities were obtained by exercise of stock options and sold under Rule 144, with dates and cash payment noted. The disclosure of prior 10b5-1 plan sales and the signature attestation regarding material information align with good governance and regulatory expectations. The size of the sale (10,000 shares) and prior 15,000-share 10b5-1 activity are small relative to total outstanding shares, suggesting limited governance or market-impact concerns. Documentation appears routine and consistent with lawful insider liquidity practices.